Vaccines and antiviral drugs in pandemic preparedness

被引:99
作者
Monto, AS [1 ]
机构
[1] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA
关键词
D O I
10.3201/eid1201.051068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
While measures such as closing schools and social distancing may slow the effects of pandemic influenza, only vaccines and antiviral drugs are clearly efficacious in preventing infection or treating illness. Unless the pandemic strain closely resembles one already recognized, vaccine will not be available early. However, studies can be con ducted beforehand to address questions concerning vaccine dose, frequency of inoculation, and need for adjuvants. In contrast, antiviral drugs, particularly the neuraminidase inhibitors, will be effective for treatment and available if stockpiling takes place. Special questions need to be answered if a highly lethal virus, such as influenza A (H5N1), produces the pandemic. Both vaccines and antiviral drugs will be required for a coordinated strategy.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 42 条
[31]   Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza [J].
Nicholson, KG ;
Colegate, AE ;
Podda, A ;
Stephenson, I ;
Wood, J ;
Ypma, E ;
Zambon, MC .
LANCET, 2001, 357 (9272) :1937-1943
[32]   Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City [J].
Olson, DR ;
Simonsen, L ;
Edelson, PJ ;
Morse, SS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11059-11063
[33]   The origin of the 1918 pandemic influenza virus: a continuing enigma [J].
Reid, AH ;
Taubenberger, JK .
JOURNAL OF GENERAL VIROLOGY, 2003, 84 :2285-2292
[34]   Characterization of a human H9N2 influenza virus isolated in Hong Kong [J].
Saito, T ;
Lim, W ;
Suzuki, T ;
Suzuki, Y ;
Kida, H ;
Nishimura, SI ;
Tashiro, M .
VACCINE, 2001, 20 (1-2) :125-133
[35]   ORIGIN OF HUMAN INFLUENZA-VIRUS SUBTYPES H2N2 AND H3N2 [J].
SCHOLTISSEK, C ;
ROHDE, W ;
VONHOYNINGEN, V ;
ROTT, R .
VIROLOGY, 1978, 87 (01) :13-20
[36]   Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy [J].
Stephenson, I ;
Bugarini, R ;
Nicholson, KG ;
Podda, A ;
Wood, JM ;
Zambon, MC ;
Katz, JM .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) :1210-1215
[37]   Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults:: phase I randomised trial [J].
Stephenson, I ;
Nicholson, KG ;
Glück, R ;
Mischler, R ;
Newman, RW ;
Palache, AM ;
Verlander, NQ ;
Warburton, F ;
Wood, JM ;
Zambon, MC .
LANCET, 2003, 362 (9400) :1959-1966
[38]   Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population [J].
Stephenson, I ;
Nicholson, KG ;
Colegate, A ;
Podda, A ;
Wood, J ;
Ypma, E ;
Zambon, M .
VACCINE, 2003, 21 (15) :1687-1693
[39]   Oral oseltamivir treatment of influenza in children [J].
Whitley, RJ ;
Hayden, FG ;
Reisinger, KS ;
Young, N ;
Dutkowski, R ;
Ipe, D ;
Mills, RG ;
Ward, P .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (02) :127-133
[40]   TRIALS OF INFLUENZA A-NEW-JERSEY-76 VIRUS-VACCINE IN NORMAL CHILDREN - OVERVIEW OF AGE-RELATED ANTIGENICITY AND REACTOGENICITY [J].
WRIGHT, PF ;
THOMPSON, J ;
VAUGHN, WK ;
FOLLAND, DS ;
SELL, SHW ;
KARZON, DT .
JOURNAL OF INFECTIOUS DISEASES, 1977, 136 :S731-S741